论文部分内容阅读
目的探讨乙型肝炎患者血清可溶性细胞间粘附分子 1(sICAM 1)水平与肝损害的关系。方法采用双抗体夹心ELISA法。检测 2 0例正常人和 6 7例HBV感染患者血清sICAM 1。结果轻、中、重度慢性乙型肝炎 (CH)患者及重型乙型肝炎 (SH)早、中、晚期患者血清sICAM 1水平 ,均显著高于正常人 ;CH患者肝功能越差、其血清sICAM 1水平越高 ;SH患者肝衰竭越重 ,其血清sICAM 1水平反而越低。HBeAg阳性或HBVDNA阳性的乙肝患者血清sICAM 1水平与HBeAg阴性和HBVDNA阴性的乙肝患者相比差异无显著性。结论在CH和SH早期 ,乙肝患者血清sICAM 1水平随着患者肝损害的加重而升高。重型肝炎患者血清sICAM 1水平随着患者肝衰竭的加重而降低 ,故sICAM 1可作为临床乙肝炎性活动和肝损害程度的监测指标
Objective To investigate the relationship between serum sICAM 1 and liver damage in hepatitis B patients. Methods 双 double antibody sandwich ELISA method. Serum sICAM 1 was detected in 20 normal subjects and 67 HBV-infected patients. Results The levels of serum sICAM 1 in patients with mild, moderate and severe chronic hepatitis B and those with early, middle and late severe hepatitis B were significantly higher than those in normal subjects. The patients with CH had worse liver function, Serum sICAM 1 levels higher; SH patients with liver failure more severe, but the lower the level of serum sICAM 1. Serum sICAM 1 levels in HBeAg-positive or HBVDNA-positive hepatitis B patients were not significantly different from those in HBeAg-negative and HBVDNA-negative hepatitis B patients. Conclusions 血 In the early stages of CH and SH, serum sICAM 1 levels in patients with hepatitis B increase with the severity of liver damage in patients. Serum levels of sICAM 1 in patients with severe hepatitis decrease with the worsening of liver failure, so sICAM 1 can be used as a monitoring indicator of the severity of hepatitis B activity and liver damage